A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical study is to determine the safety, tolerability, pharmacokinetics
and activity of once-daily (QD) oral dosing of VT-464, a lyase-selective inhibitor of CYP17,
in patients with castration-resistant prostate cancer (CRPC).